Xeris Biopharma Holdings, Inc. 8-K

What Happened

• On March 2, 2026, Xeris Biopharma Holdings, Inc. announced its results of operations and business highlights for the three- and twelve-month periods ended December 31, 2025 via a press release furnished as Exhibit 99.1 to a Form 8‑K (Item 2.02).
• The Form 8‑K was signed by Steven M. Pieper, Chief Financial Officer.

Key Details

• Filing date: March 2, 2026 (Form 8‑K).
• Reporting periods: three months and twelve months ended December 31, 2025 (Q4 and full-year 2025).
• Press release furnished as Exhibit 99.1 to the Form 8‑K; investors should review that exhibit for the specific financial figures and business highlights.
• The filing also includes the standard Inline XBRL cover page (Exhibit 104).

Why It Matters

• This 8‑K notifies investors that Xeris has released its latest quarterly and annual financial results—key data points for assessing recent earnings, revenue, profitability, cash position, and management commentary.
• Retail investors should read the furnished press release (Exhibit 99.1) to see the company’s reported numbers and any forward-looking comments or business highlights that could affect near-term performance.